Recurrent Bladder Cancer
26
1
2
15
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
23.1%
6 terminated out of 26 trials
71.4%
-15.1% vs benchmark
4%
1 trials in Phase 3/4
60%
9 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (26)
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
Afatinib in Advanced Refractory Urothelial Cancer
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?
Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu